Dividendos de Janux Therapeutics

Dividendo controles de criterios 0/6

Janux Therapeutics no tiene historial de pago de dividendo.

Información clave

n/a

Rentabilidad por dividendo

n/a

Ratio de pago

Rentabilidad media de la industria	2.9%
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Beneficios por acción	-US$1.07
Rentabilidad por dividendo prevista a 3 años	0%

Últimas actualizaciones de dividendos

No hay actualizaciones

Recent updates

Janux Therapeutics: A Prime Target In Cancer Care's M&A Game

Apr 11

Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024

Feb 27

Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth

Feb 24

Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?

Dec 29

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Nov 04

We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely

Jul 20

A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)

May 23

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Feb 09

We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth

Oct 19

Janux Therapeutics GAAP EPS of -$0.41, revenue of $2.37M

Aug 09

We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth

Jun 05

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Feb 19

Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Nov 03

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de JANX han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de JANX han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Janux Therapeutics vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de JANX con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (JANX)	n/a
Suelo de mercado 25% (US)	1.5%
Techo de mercado 25% (US)	4.7%
Media de la industria (Biotechs)	2.9%
Previsión de analistas en 3 años (JANX)	0%

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de JANX en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de JANX en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de JANX para determinar si sus pagos de dividendos están cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que JANX no ha comunicado ningún pago.

Dividendos de Janux Therapeutics

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos

Recent updates

First quarter 2024 earnings released: US$0.30 loss per share (vs US$0.42 loss in 1Q 2023)

Janux Therapeutics, Inc., Annual General Meeting, Jun 26, 2024

Janux Therapeutics: A Prime Target In Cancer Care's M&A Game

Consensus EPS estimates upgraded to US$1.43 loss, revenue downgraded

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Janux Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $296.497596 million.

Janux Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $296.497596 million.

Janux Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $175 million.

Price target increased by 36% to US$37.34

Now 186% overvalued after recent price rise

Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024

Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth

Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo to Chief Scientific Officer

Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?

Consensus revenue estimates increase by 37%

New minor risk - Share price stability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Consensus revenue estimates increase by 11%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely

New minor risk - Shareholder dilution

Consensus revenue estimates fall by 11%

Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1A Dose Escalation for Psma-Tractr Janx007 and an Update on Pipeline Programs

Now 20% undervalued

Nasdaq Acknowledges Janux Therapeutics’s Non-Compliance with Listing Rule 5605(b)(1)

A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)

Now 23% undervalued after recent price drop

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.3% to US$27.50

Now 23% undervalued after recent price drop

Now 21% undervalued after recent price drop

Consensus revenue estimates increase by 85%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Janux Therapeutics, Inc. Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors

Consensus revenue estimates increase by 23%

Price target decreased to US$29.67

Less than half of directors are independent

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth

Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer

Janux Therapeutics, Inc Appoints Brenda Van Vreeswyk as Head of Human Resources

Janux Therapeutics Appoints Winston Kung to Board of Directors

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Janux Therapeutics GAAP EPS of -$0.41, revenue of $2.37M

Janux Therapeutics, Inc.(NasdaqGM:JANX) dropped from Russell 2000 Growth Index

We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth

Janux Therapeutics, Inc. Announces Fda Clearance of Investigational New Drug Application for Janx007, A Psma-Tractr for Metastatic Castration-Resistant Prostate Cancer

Janux Therapeutics, Inc. Announces Fda Clearance of Investigational New Drug Application for Janx007, A Psma-Tractr for Metastatic Castration-Resistant Prostate Cancer

Consensus revenue estimates increase by 57%

Janux Therapeutics, Inc., Annual General Meeting, Jun 14, 2022

High number of new directors

Janux Therapeutics, Inc. to Present Preclinical Data at the 18th Annual PEGS Boston for PSMA-TRACTr and EGFR-TRACTr

Consensus forecasts updated

Consensus forecasts updated

Janux Therapeutics, Inc. Appoints Byron Robinson as Chief Strategy Officer

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

High number of new directors

Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Insider recently bought US$1m worth of stock

Janux Therapeutics, Inc. has completed an IPO in the amount of $193.8 million.

Estabilidad y crecimiento de los pagos

Rentabilidad por dividendo vs. Mercado

Pago de beneficios a los accionistas

Pago en efectivo a los accionistas

Discover strong dividend paying companies